3billion Secures 30 Billion KRW to Scale AI-Driven Genetic Diagnostics in U.S. Market

3billion Secures 30 Billion KRW to Scale AI-Driven Genetic Diagnostics in U.S. Market

AI-based rare disease diagnostic company 3billion has raised 30 billion KRW through a hybrid financing structure consisting of 17.5 billion KRW in convertible preferred shares (CPS) and 12.5 billion KRW in convertible bonds (CB). The funding round included participation from major institutional investors such as Kiwoom PE, GVA Asset Management, and IBK Industrial Bank of Korea. Notably, the convertible bonds were issued with a 0% coupon rate and 0% yield to maturity, signaling high investor confidence in the company's technological growth despite the prevailing high-interest-rate environment.

This capital injection is significant for the AI healthcare sector as it facilitates the expansion of AI-driven genomic interpretation from clinical diagnosis into the preventive care market. 3billion intends to utilize the funds to build infrastructure in the United States, targeting a rare disease market of approximately 30 million people through insurance-based, high-value-added diagnostic models. The company is also shifting its business model from reactive patient diagnosis to proactive genetic risk management through whole-genome sequencing (WGS)-based newborn screening (gNBS) and its 'Family Insight' testing service.

From an industry perspective, 3billion’s move represents a strategic convergence of AI diagnostics and AI-driven drug discovery. By accelerating the preclinical validation of 15 drug development pipelines generated via its AI platform, the company is positioning itself to create a dual-revenue stream: diagnostic services for prevention and management, and potential licensing deals (L/O) with pharmaceutical companies. The ability to secure zero-interest debt suggests that the market views their AI-driven genomic analysis as a high-conviction asset capable of outperforming traditional capital costs.